에이치엘비 HLB

HOME

UNITE (Universal Intracellular Targeted Expression),
a next-generation immunotherapy vaccine platform owned by Immunomic Therapeutics,
is being used to develop therapeutic vaccines for cancer, allergies, and
animals, enhancing the function of cytotoxic T cells.

Immune system activation mechanism

The UNITE platform technology is a powerful next-generation vaccine platform that targets specific antigens to the lysosomes of dendritic cells (DC), enhancing antigen presentation capabilities and activating cytotoxic T cells. This enhanced immune function is a highly scalable platform technology that attacks specific antigens.

Indications

What is glioblastoma?

Glioblastoma is a primary tumor that arises from the brain or spinal cord tissue, or from the membranes surrounding them. It originates from neuroglial cells, which are normally abundant in brain tissue. Glioblastoma is a grade 4 astrocytoma and the most malignant type among astrocytomas. Histologically, it is characterized as an anaplastic astrocytoma with added necrotic areas. This tumor is the most common primary brain tumor, accounting for half of all gliomas and 15% of pediatric gliomas. It is rare for glioblastoma to occur in the cerebellum. According to the WHO classification revised in 2000, glioblastoma includes variants such as giant cell glioblastoma and gliosarcoma. * Source: National Cancer Information Center

Pipeline

Clinical trial status

01.

Glioblastoma first-line treatment

A phase 2 clinical trial is being conducted with ITI-1000 (pp65-LAMP DC) therapy for the first-line treatment of glioblastoma.

View Details

UNITE (Universal Intracellular Targeted Expression), a next-generation immunotherapy vaccine platform owned by Immunomic Therapeutics, is being used to develop therapeutic vaccines for cancer, allergies, and animals, enhancing the function of cytotoxic T cells.